BiotechTube

varegacestat

Phase 1Completed
0 watching 0 views this week💤 Quiet
28
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Healthy Volunteer

Conditions

Healthy Volunteer, Hepatic Impairment (HI)

Trial Timeline

Mar 7, 2025 → Mar 6, 2026

NCT ID
NCT06841315

About varegacestat

varegacestat is a phase 1 stage product being developed by Immunome for Healthy Volunteer. The current trial status is completed. This product is registered under clinical trial identifier NCT06841315. Target conditions include Healthy Volunteer, Hepatic Impairment (HI).

Hype Score Breakdown

Clinical
10
Activity
5
Company
5
Novelty
3
Community
2

Clinical Trials (2)

NCT IDPhaseStatus
NCT06841315Phase 1Completed
NCT06845852Phase 1Completed

Competing Products

20 competing products in Healthy Volunteer

See all competitors
ProductCompanyStageHype Score
AZD0837AstraZenecaPhase 1
33
ValsartanNovartisPhase 1
33
CSL112 + PlaceboCSLPhase 1
32
UT-15CUnited TherapeuticsPhase 1
30
VNA-318 + PlaceboBiotrialPhase 1
25
Open-label TRV734 125 mg + TRV734 blinded + Oxycodone IR 10 mg + PlaceboTrevenaPhase 1
25
TRV130 + Moxifloxacin + PlaceboTrevenaPhase 1
25
Radiolabeled TRV130TrevenaPhase 1
25
TRV130A + Dextrose in WaterTrevenaPhase 1
25
TRV734TrevenaPhase 1
25
ALT02 + EU-licensed Herceptin + US-licensed HerceptinAlteogenPhase 1
33
ENZ215 + EU Sourced Prolia + US Sourced ProliaAlkem LaboratoriesPhase 1
33
KPL-404Kiniksa PharmaceuticalsPhase 1
28
MORF-057 + Placebo for MORF-057Eli LillyPhase 1
33
Propranolol + PseudoephedrineEli LillyPre-clinical
23
LY2157299Eli LillyPhase 1
33
Lasmiditan + PlaceboEli LillyPhase 1
33
LY3015014 + PlaceboEli LillyPhase 1
33
LOXO-783Eli LillyPhase 1
33
LY2541546 - IV + LY2541546 - SC + PlaceboEli LillyPhase 1
33

Other Products from Immunome

AL102Phase 2/3
60
varegacestat + Itraconazole (200 mg)Phase 1
28
varegacestatPhase 1
28
IM-1021Phase 1
28
IMM-BCP-01 + PlaceboPhase 1
28